5 Common Myths About Schedule III & The Truth About What Cannabis Rescheduling Means
Cannabis rescheduling potential under Schedule III does not immediately expand research access due to ongoing DEA restrictions. This limitation maintains the clinical evidence gap that challenges prescribing decisions. Understanding these regulatory…
Editorial: Cannabis is not as benign as we too often tend to believe
Cannabis driving impairment risk is a critical concern for clinicians counseling patients. Users often overestimate their driving abilities despite evidence of increased accident risk. Understanding this risk helps guide safer patient practices.
Children’s National Hospital Sees More Cannabis Addiction Among Teens and Tweens
Adolescent cannabis addiction risk is increasing due to the higher THC concentrations in modern cannabis products. Children's National Hospital reports more cases of cannabis use disorder among teens and tweens. Clinicians must update screening and…
Research on Cannabis Use and Behavioral Outcomes in Children with ASD
Peripregnancy cannabis exposure behavioral outcomes show varied effects on children with and without ASD symptoms. This research highlights differences in behavioral and developmental associations. Understanding these outcomes is crucial for counseling…
Endocannabinoid System & GLP-1 Mental Health Evidence
GLP-1 receptor agonists mental health evidence suggests these drugs may influence psychiatric disorder risks. Genetic studies indicate potential benefits for schizophrenia. Patients should discuss mental health implications with clinicians.
Cannabinoid Clinical Trials: Teen Cannabis Intervention Study
This study evaluates a rebuttal-based social norms-tailored cannabis intervention designed to improve prevention messaging for at-risk adolescents. Personalized approaches challenge negative reactions to standard cannabis messages. Findings support…
Endocannabinoid System Research: Cannabis in HIV Care
Digital therapeutics HIV smoking cessation research shows strong feasibility and acceptability among people living with HIV. This approach offers scalable cessation tools for this high-risk population. Tobacco use remains a leading cause of illness and…
Cannabidiol for Lennox-Gastaut: Cannabinoid Clinical Trials
Clinically meaningful reduction in drop seizures has been observed in Lennox-Gastaut syndrome patients treated with cannabidiol. Clinical trials show that even reductions below 50% can improve patient quality of life. Caregiver-reported outcomes align…
Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
Transdermal cannabidiol gel fragile x syndrome safety data comes from ongoing clinical trials evaluating long-term tolerability in children and adolescents. This synthetic CBD formulation targets behavioral symptoms linked to endocannabinoid…
Cannabinoid Clinical Trials: CBD, WADA, and Urine Testing Insights
Broad-spectrum CBD supplements doping risk is a critical concern for athletes subject to anti-doping rules. This study found that daily use of broad-spectrum CBD can produce detectable WADA-prohibited cannabinoids in urine. Exercise further amplifies…
